Puma Biotechnology, Inc. (PBYI)Healthcare | Biotechnology | Los Angeles, United States | NasdaqGS
7.37 USD
+7.37
(-1.339%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:43 p.m. EDT
Despite bearish analyst consensus (all targets at $5.00) and negative forecast model predictions, the options flow is aggressively bullish, positioning capital for a move to $10.00 within weeks. The disconnect between the technical divergence (crossing above the 200-day MA) and the buy-side positioning at higher strikes suggests a speculative 'momentum play' is underway, betting on a re-acceleration of growth given the 27% revenue growth and improving profitability. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.067573 |
| AutoETS | 0.067979 |
| AutoTheta | 0.110767 |
| AutoARIMA | 0.167058 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 2.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.231 |
| Excess Kurtosis | -1.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.901 |
| Revenue per Share | 4.566 |
| Market Cap | 374,959,712 |
| Trailing P/E | 12.08 |
| Forward P/E | 11.34 |
| Beta | 1.18 |
| Profit Margins | 13.62% |
| Website | https://www.pumabiotechnology.com |
As of April 18, 2026, 10:43 p.m. EDT: Options market exhibits a strong bullish skew. Call Open Interest (OI) is heavily concentrated out-of-the-money at the $10.00 strike for most expirations, with the largest volume and OI placed there for the May contract. The $7.50 strike serves as a high-volume anchor across all call tenors. Conversely, put activity is minimal and distant, with low OI at strikes significantly below current price (e.g., $2.50 - $5.00), indicating a lack of hedging interest or downside positioning. Implied volatility for deep OTM calls (10.0) is elevated compared to ATM calls, suggesting speculators are pricing in a higher probability of upside movement or a significant gap to the upside.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4485049 |
| Address1 | 10,880 Wilshire Boulevard |
| Address2 | Suite 1700 |
| All Time High | 279.37 |
| All Time Low | 1.6 |
| Ask | 7.42 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 307,950 |
| Average Daily Volume3 Month | 393,201 |
| Average Volume | 393,201 |
| Average Volume10Days | 307,950 |
| Beta | 1.177 |
| Bid | 7.34 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 2.586 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.37 |
| Current Ratio | 2.002 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.5 |
| Day Low | 7.32 |
| Debt To Equity | 21.901 |
| Display Name | Puma Biotechnology |
| Earnings Call Timestamp End | 1,772,141,400 |
| Earnings Call Timestamp Start | 1,772,141,400 |
| Earnings Growth | -0.344 |
| Earnings Quarterly Growth | -0.304 |
| Earnings Timestamp | 1,772,139,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | 47,437,000 |
| Ebitda Margins | 0.20772 |
| Enterprise To Ebitda | 6.45 |
| Enterprise To Revenue | 1.34 |
| Enterprise Value | 305,977,696 |
| Eps Current Year | 0.4 |
| Eps Forward | 0.65 |
| Eps Trailing Twelve Months | 0.61 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.6838 |
| Fifty Day Average Change | 0.68619967 |
| Fifty Day Average Change Percent | 0.102666095 |
| Fifty Two Week Change Percent | 144.8505 |
| Fifty Two Week High | 7.9 |
| Fifty Two Week High Change | -0.5300002 |
| Fifty Two Week High Change Percent | -0.067088634 |
| Fifty Two Week Low | 2.85 |
| Fifty Two Week Low Change | 4.52 |
| Fifty Two Week Low Change Percent | 1.5859649 |
| Fifty Two Week Range | 2.85 - 7.9 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,335,274,200,000 |
| Float Shares | 39,005,985 |
| Forward Eps | 0.65 |
| Forward P E | 11.338462 |
| Free Cashflow | 30,693,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 179 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.74534 |
| Gross Profits | 170,214,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15635 |
| Held Percent Institutions | 0.72644997 |
| Implied Shares Outstanding | 50,876,487 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California. |
| Long Name | Puma Biotechnology, Inc. |
| Market | us_market |
| Market Cap | 374,959,712 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_128739842 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 31,111,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 380,301,740 |
| Number Of Analyst Opinions | 1 |
| Open | 7.45 |
| Operating Cashflow | 41,802,000 |
| Operating Margins | 0.22670999 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 424 248 6500 |
| Previous Close | 0.0 |
| Price Eps Current Year | 18.425 |
| Price Hint | 2 |
| Price To Book | 2.8499613 |
| Price To Sales Trailing12 Months | 1.6418884 |
| Profit Margins | 0.13623 |
| Quick Ratio | 1.861 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 7.37 |
| Regular Market Change Percent | -1.33869 |
| Regular Market Day High | 7.5 |
| Regular Market Day Low | 7.32 |
| Regular Market Day Range | 7.32 - 7.5 |
| Regular Market Open | 7.45 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 7.37 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 213,992 |
| Return On Assets | 0.10852 |
| Return On Equity | 0.27969 |
| Revenue Growth | 0.277 |
| Revenue Per Share | 4.566 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 50,876,487 |
| Shares Percent Shares Out | 0.0774 |
| Shares Short | 3,936,887 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,764,191 |
| Short Name | Puma Biotechnology Inc |
| Short Percent Of Float | 0.090299994 |
| Short Ratio | 11.43 |
| Source Interval | 15 |
| State | CA |
| Symbol | PBYI |
| Target High Price | 5.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 97,528,000 |
| Total Cash Per Share | 1.917 |
| Total Debt | 28,546,000 |
| Total Revenue | 228,371,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | 0.61 |
| Trailing P E | 12.081966 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.4639 |
| Two Hundred Day Average Change | 1.9060998 |
| Two Hundred Day Average Change Percent | 0.34885335 |
| Type Disp | Equity |
| Volume | 213,992 |
| Website | https://www.pumabiotechnology.com |
| Zip | 90,024 |